Azzad Asset Management’s Genomic Health, Inc. GHDX Stock Holding History

Azzad Asset Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,943	Closed	-$374K	–	317
2017 Q4	$374K	Buy	10,943 +136	+1%	+$4.34K	0.12%	238
2017 Q3	$347K	Buy	10,807 +137	+1%	+$4.32K	0.12%	246
2017 Q2	$347K	Buy	10,670 +168	+2%	+$5.32K	0.12%	233
2017 Q1	$331K	Buy	10,502 +161	+2%	+$4.76K	0.12%	227
2016 Q4	$304K	Hold	10,341	–	–	0.13%	218
2016 Q3	$299K	Buy	10,341 +286	+3%	+$7.97K	0.12%	222
2016 Q2	$260K	Buy	10,055 +182	+2%	+$4.83K	0.11%	226
2016 Q1	$245K	Sell	9,873 -2,179	-18%	-$59.8K	0.11%	224
2015 Q4	$424K	Buy	+12,052	New	+$323K	0.2%	174
2015 Q3	–	Sell	-8,258	Closed	-$230K	–	262
2015 Q2	$230K	Sell	8,258 -61	-0.7%	-$1.72K	0.12%	236
2015 Q1	$254K	Buy	8,319 +395	+5%	+$12.6K	0.12%	242
2014 Q4	$253K	Buy	7,924 +376	+5%	+$12.2K	0.13%	254
2014 Q3	$214K	Sell	7,548 -598	-7%	-$16.7K	0.12%	272
2014 Q2	$223K	Buy	+8,146	New	+$217K	0.13%	258

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Azzad Asset Management's GHDX Position: Q1 2018 in Review

Azzad Asset Management sold out of Genomic Health, Inc. (GHDX) in Q1 2018, closing a stake of 10,943 shares — an estimated $374K sold.

Azzad Asset Management first reported a position in GHDX in Q2 2014 and held it in 14 quarters. The position peaked at $424K in Q4 2015. 134 funds tracked by Wall St. Rank hold GHDX as of Q1 2018.

Azzad Asset Management reported no remaining Genomic Health, Inc. position as of Q1 2018 after selling out during the quarter.
Azzad Asset Management sold 10,943 Genomic Health, Inc. shares in Q1 2018, an estimated $374K.
Azzad Asset Management first reported a position in Genomic Health, Inc. in Q2 2014 and held it in 14 quarters.
Azzad Asset Management's Genomic Health, Inc. position peaked at $424K in Q4 2015.
134 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2018.

Based on Azzad Asset Management's 13F filing for Q1 2018, filed 3 Apr 2024.